Cti Biopharma reported $21.5M in Selling and Administration Expenses for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Baxter International BAX:US USD 782M 35M
Bristol Myers Squibb BMY:US USD 1.93B 147M
Cti Biopharma CTIC:US USD 21.5M 92K
Cytori Therapeutics CYTX:US USD 2.22M 67K
Eli Lilly And LLY:US USD 1.61B 10.9M
Geron GERN:US USD 15.64M 8.2M
Mirati Therapeutics MRTX:US USD 60.8M 6.57M
Northwest Biotherapeutics NWBO:US USD 8.13M 199K
Novartis NOVN:VX USD 3.4B 185M
Novartis NVS:US USD 3.7B 295M
Seattle Genetics SGEN:US USD 210.38M 9.88M
Teva Pharmaceutical Industries TEVA:US USD 777M 72M
YTE INCY:US USD 266.46M 13.18M